» Articles » PMID: 26486570

Integrative Metabonomics As Potential Method for Diagnosis of Thyroid Malignancy

Overview
Journal Sci Rep
Specialty Science
Date 2015 Oct 22
PMID 26486570
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

Thyroid nodules can be classified into benign and malignant tumors. However, distinguishing between these two types of tumors can be challenging in clinics. Since malignant nodules require surgical intervention whereas asymptomatic benign tumors do not, there is an urgent need for new techniques that enable accurate diagnosis of malignant thyroid nodules. Here, we used (1)H NMR spectroscopy coupled with pattern recognition techniques to analyze the metabonomes of thyroid tissues and their extracts from thyroid lesion patients (n = 53) and their adjacent healthy thyroid tissues (n = 46). We also measured fatty acid compositions using GC-FID/MS techniques as complementary information. We demonstrate that thyroid lesion tissues can be clearly distinguishable from healthy tissues, and malignant tumors can also be distinguished from the benign tumors based on the metabolic profiles, both with high sensitivity and specificity. In addition, we show that thyroid lesions are accompanied with disturbances of multiple metabolic pathways, including alterations in energy metabolism (glycolysis, lipid and TCA cycle), promotions in protein turnover, nucleotide biosynthesis as well as phosphatidylcholine biosynthesis. These findings provide essential information on the metabolic features of thyroid lesions and demonstrate that metabonomics technology can be potentially useful in the rapid and accurate preoperative diagnosis of malignant thyroid nodules.

Citing Articles

Reprogramming of Thyroid Cancer Metabolism: from Mechanism to Therapeutic Strategy.

Wan Y, Li G, Cui G, Duan S, Chang S Mol Cancer. 2025; 24(1):74.

PMID: 40069775 PMC: 11895238. DOI: 10.1186/s12943-025-02263-4.


Blood metabolites reflect the effect of gut microbiota on differentiated thyroid cancer: a Mendelian randomization analysis.

Zhang H, Li Y, Li L BMC Cancer. 2025; 25(1):368.

PMID: 40022019 PMC: 11869591. DOI: 10.1186/s12885-025-13598-y.


Non-invasive diagnosis of papillary thyroid microcarcinoma using a novel metabolomics analysis of urine.

Zhao M, Li R, Miao C, Miccoli P, Lu J Endocrine. 2024; 87(3):1100-1111.

PMID: 39580767 DOI: 10.1007/s12020-024-04105-7.


The influence of cancer on the reprogramming of lipid metabolism in healthy thyroid tissues of patients with papillary thyroid carcinoma.

Zwara A, Hellmann A, Czapiewska M, Korczynska J, Sztendel A, Mika A Endocrine. 2024; 87(1):273-280.

PMID: 39145825 PMC: 11739254. DOI: 10.1007/s12020-024-03993-z.


Effects of Early Life Exposures to the Aryl Hydrocarbon Receptor Ligand TCDF on Gut Microbiota and Host Metabolic Homeostasis in C57BL/6J Mice.

Tian Y, Rimal B, Bisanz J, Gui W, Wolfe T, Koo I Environ Health Perspect. 2024; 132(8):87005.

PMID: 39140734 PMC: 11323762. DOI: 10.1289/EHP13356.


References
1.
Song Q, Wang D, Lou Y, Li C, Fang C, He X . Diagnostic significance of CK19, TG, Ki67 and galectin-3 expression for papillary thyroid carcinoma in the northeastern region of China. Diagn Pathol. 2011; 6:126. PMC: 3264507. DOI: 10.1186/1746-1596-6-126. View

2.
Nikiforov Y, Carty S, Chiosea S, Coyne C, Duvvuri U, Ferris R . Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next-generation sequencing assay. Cancer. 2014; 120(23):3627-34. PMC: 7737376. DOI: 10.1002/cncr.29038. View

3.
Warburg O . On the origin of cancer cells. Science. 1956; 123(3191):309-14. DOI: 10.1126/science.123.3191.309. View

4.
Castro M, Gharib H . Thyroid fine-needle aspiration biopsy: progress, practice, and pitfalls. Endocr Pract. 2003; 9(2):128-36. DOI: 10.4158/EP.9.2.128. View

5.
Estrela J, Ortega A, Obrador E . Glutathione in cancer biology and therapy. Crit Rev Clin Lab Sci. 2006; 43(2):143-81. DOI: 10.1080/10408360500523878. View